행사/교육
Asia Antibody Congress 2013
- 등록일2013-05-20
- 조회수4554
- 구분 국외
- 행사교육분류 행사
-
주관기관
Terrapinn Pte Ltd
-
행사장소
Grand Copthorne Waterfront - Singapore
-
행사기간
2013-06-17 ~ 2013-06-20
- 원문링크
- 첨부파일
2.pdf
Asia Antibody Congress 2013
Overview
Asia Antibody Congress 2013 will serve as a strategic platform for pharmas, biotechs, research institutes and solution providers to discuss key strategies to expedite business development, scientific advancement and partnerships for their antibody business.
Showcasing major global trends, clinical breakthroughs, best practices and 1 to 1 partnering opportunities, this event delivers unrivalled industry participation across the antibody value chain in Asia.
conference programme
18th June 2013, Tuesday
Conference Day One
08.00 Registration and refreshments
08.50 Chairman’s opening remarks
MARKET OPPORTUNITIES IN ASIA
09.00 Keynote Panel: Clinical opportunities, challenges and effective strategies to expand clinical operations in Asia
› Harsukh Parmar, Vice President, Global Head of Translational & Experimental Medicine, Roche, United States› Gilles Picard, Vice President for Asia, Australia, Africa & Middle East, AbbVie, Singapore
Keynote Panel: Clinical opportunities, challenges and effective strategies to expand clinical operations in Asia
09.40 Capitalising on Asia’s potential: Strategic alliance between global and Asian antibody companies to propel growth in global antibody development
› Gilles Picard, Vice President for Asia, Australia, Africa & Middle East, AbbVie, Singapore
Capitalising on Asia’s potential: Strategic alliance between global and Asian antibody companies to propel growth in global antibody development
10.10 Win-win partnering – business models and learning from partnering in Asia
› Roxanne Duan, Director, Academic Partnering, MedImmune, United States
Win-win partnering – business models and learning from partnering in Asia
10.40 Morning refreshments and exhibition visit
NEW DEVELOPMENTS IN THERAPEUTIC ANTIBODIES
11.20 Advancing innovation and human target validation using biologic therapies to understand disease pathways and improve R&D productivity
› Harsukh Parmar, Vice President, Global Head of Translational & Experimental Medicine, Roche, United States
Advancing innovation and human target validation using biologic therapies to understand disease pathways and improve R&D productivity
11.50 Uncovering translational strategies for mAb development in immunology
› Dr. Francisco Leon, Vice President & Head Immunology Translational Medicine, Johnson & Johnson, United States
Uncovering translational strategies for mAb development in immunology
12.20 Development of an immune check point pipeline for mAbs in oncology
› Dr. Robert F. Burns, CEO, 4-Antibody, Switzerland
Development of an immune check point pipeline for mAbs in oncology
12.50 Networking luncheon and exhibition visit
OPTIMISING STRUCTURE FUNCTION
14.00 How to select the best candidate for biotherapeutics drug development
› Dr. Steffen Hartmann, Global Head Protein Developability, Novartis, Switzerland
How to select the best candidate for biotherapeutics drug development
14.30 Production, characterization and therapeutic potential of two mAbs targeting different neoepitopes in prefibrillar pathogenic tau
› Daniel G. Chain, Chairman & CEO, Intellect Neurosciences, United States
Production, characterization and therapeutic potential of two mAbs targeting different neoepitopes in prefibrillar pathogenic tau
15.00 Stable human antibody therapeutics
› Dr. Daniel Christ, Director Therapeutic Antibody Development, Garvan Institute of Medical Research, Australia
Stable human antibody therapeutics
15.30 Afternoon refreshments and exhibition visit
mAb PRODUCTION AND SCALE-UP
16.00 mAb process design and scale up to 1000L single use multiproduct GMP facilities
› Bo Kara, Director Science and Technology, Fujifilm Diosynth Biotechnologies, United Kingdom
mAb process design and scale up to 1000L single use multiproduct GMP facilities
16.30 Strategies for mAb CMC development and scale-up
› Dr. Jens Sigurd Okkels, Vice President and Head of CMC Center Europe, Takeda, Germany
Strategies for mAb CMC development and scale-up
17.00 CMC Process Development & Manufacturing Stage Gate Strategy and CQA Evaluation for Branded & Biosimilar mAbs
› Dr. David Jen, Director of Biologic Process Development, Aeras, United States
CMC Process Development & Manufacturing Stage Gate Strategy and CQA Evaluation for Branded & Biosimilar mAbs
17.30 Chairman’s closing remarks
17.40 End of conference day one
........(계속)
☞ 자세한 내용은 내용바로가기를 이용하시기 바랍니다.